Developing a Canadian Real-World Evidence Action Plan across the Drug Life Cycle

Policy makers face challenges with the number of drugs for rare indications and rapidly rising costs. In facing these challenges, decision-makers see real-world evidence (RWE) as an opportunity. Health Canada and the Canadian Agency for Drugs and Technologies in Health (CADTH) recently announced the...

Descripción completa

Detalles Bibliográficos
Autores principales: Tadrous, Mina, Ahuja, Tarry, Ghosh, Basanti, Kropp, Rhonda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Longwoods Publishing 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294449/
https://www.ncbi.nlm.nih.gov/pubmed/32538348
http://dx.doi.org/10.12927/hcpol.2020.26225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294449/
https://www.ncbi.nlm.nih.gov/pubmed/32538348
http://dx.doi.org/10.12927/hcpol.2020.26225

Ejemplares similares